|
Mansi Sharma
Vishal Garg
Kajal Gupta
Keywords:
Cardiovascular drugs; Hypertension; Heart failure; Dyslipidemia; SGLT2 inhibitors; PCSK9 inhibitors; RNA therapeutics; Lipoprotein(a); Precision medicine; Pharmacological innovations.
Abstract:
Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, necessitating continuous advancements in pharmacotherapy. Recent years (2024-2025) have witnessed a paradigm shift from conventional symptom control to disease-modifying and precision-based therapies. In hypertension, novel agents such as aldosterone synthase inhibitors and endothelin receptor antagonists provide effective control in resistant cases. Heart failure management has significantly evolved with sodium-glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists, and dual incretin therapies demonstrating improved survival and reduced hospitalization. In dyslipidemia, RNA-based therapies targeting lipoprotein(a), PCSK9 inhibitors, and ANGPTL3 inhibitors have emerged as powerful tools for lipid reduction and cardiovascular risk management. These pharmacological innovations emphasize targeted mechanisms, long-acting formulations, and personalized medicine approaches, offering improved clinical outcomes and transforming the future of cardiovascular therapeutics.
|
|
International Journal of Recent Research and Review
ISSN: 2277-8322
Vol. XIX, Issue 1
January 2026
|
PDF View
PUBLISHED
January 2026
ISSUE
Vol. XIX, Issue 1
SECTION
Articles
|
